Results 81 to 90 of about 26,674 (238)

Type 1 diabetes [PDF]

, 2018
Type 1 diabetes is a chronic autoimmune disease characterised by insulin deficiency and resultant hyperglycaemia. Knowledge of type 1 diabetes has rapidly increased over the past 25 years, resulting in a broad understanding about many aspects of the ...
DiMeglio, Linda A., Evans-Molina, Carmella, Oram, Richard A.   +2 more
core   +1 more source

Impact of evolving treatment patterns on interstitial lung disease progression in systemic sclerosis using the EUSTAR database

Arthritis &Rheumatology, Accepted Article.
Background The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasing immunosuppressive (IST) and anti‐fibrotic therapies available. However, their real‐world use remains unclear. Objectives To analyze treatment trends and the effect of IST and anti‐fibrotic therapies on ILD progression ...
Corrado Campochiaro, Marie‐Elise Truchetet, Madelon Vonk, Giacomo De Luca, Giovanna Cuomo, Lidia P. Ananieva, Eric Hachulla, Vanessa Smith, Ana Maria Gheorghiu, Radim Becvar, Patricia Carreira, Nicolas Hunzelmann, Daniel E. Furst, Vera Ortiz‐Santamaria, Francesco Del Galdo, Marco Matucci‐Cerinic, Anna‐Maria Hoffmann‐Vold, EUSTAR collaborators   +17 more
wiley   +1 more source

Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis

Arthritis Research & Therapy
Background The biological mechanisms underlying the differential response to abatacept in patients with rheumatoid arthritis (RA) are unknown. Here, we aimed to identify cellular, transcriptomic, and proteomic features that predict resistance to ...
T. Iwasaki, R. Watanabe, H. Ito, T. Fujii, K. Ohmura, Hiroyuki Yoshitomi, K. Murata, K. Murakami, A. Onishi, Masao Tanaka, S. Matsuda, Fumihiko Matsuda, A. Morinobu, M. Hashimoto   +13 more
semanticscholar   +1 more source

Benefit of B7-1 staining and abatacept for treatment-resistant post-transplant focal segmental glomerulosclerosis in a predominantly pediatric cohort: time for a reappraisal

Pediatric nephrology (Berlin, West), 2022
Background Primary FSGS manifests with nephrotic syndrome and may recur following KT. Failure to respond to conventional therapy after recurrence results in poor outcomes.
G. Burke, Jayanthi Chandar, J. Sageshima, Mariella Ortigosa-Goggins, P. Amarapurkar, A. Mitrofanova, Marissa Defreitas, C. Katsoufis, W. Seeherunvong, Alexandra Centeno, Javier Pagan, L. A. Mendez-Castaner, A. Mattiazzi, W. Kupin, G. Guerra, Linda J. Chen, M. Morsi, J. Figueiró, R. Vianna, C. Abitbol, D. Roth, A. Fornoni, P. Ruiz, G. Ciancio, E. Garin   +24 more
semanticscholar   +1 more source

Serum Proteomic Signatures of RA Risk and Response: Analysis of the APIPPRA Trial

Arthritis &Rheumatology, Accepted Article.
Objective To identify serum protein signatures associated with progression to rheumatoid arthritis (RA) and response to abatacept in at‐risk individuals. Methods A total of 440 serum samples from 118 APIPPRA study participants were selected from baseline to RA onset for 46 RA progressors or to study end for 72 participants who did not develop RA ...
Marianna Jasenecova, Carl Coyle, Alina Mihalovits, Sarah Ryan, Elizabeth Pook, Esperanza Perucha, Gabrielle Harker, Melody Chin, Sam Norton, Andrew P. Cope   +9 more
wiley   +1 more source

Abatacept [PDF]

British Journal of Clinical Pharmacology, 2009
Eline A, Dubois, Adam F, Cohen
  +5 more sources

Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis

Immunological Medicine, 2019
The aim of this study was to assess abatacept in rheumatoid arthritis (RA) patient. Patients (20 men, 89 women, aged 61.9 ± 10.4 y) who responded inadequately to conventional synthetic disease-modifying anti-rheumatic drug were treated with abatacept for
Noriyoshi Ogawa, Hiroyuki Ohashi, Yasuhiro Ota, Kaori Kobori, Motohiro Suzuki, Seiji Tsuboi, Masakatsu Hayakawa, Yoshinori Goto, Taro Karahashi, Osamu Kimoto, Toshiaki Miyamoto, Shogo Furukawa, Kumiko Shimoyama, Daisuke Suzuki, Yuichiro Maekawa   +14 more
doaj   +1 more source

PMS48 Cost-Effectiveness of Tocilizumab for The Management of Inadequately Responding Rheumatoid Arthritis Patients [PDF]

, 2003
Weiner, LawrencePrimer pla de l'obra. Tres grans paral·lelepípedes de formigó, amb aparença de sarcòfags.Repartits al llarg de l'avinguda.
Hansen, R.N., Best, J.H., Sullivan, S.D., Carlson, J.J.   +3 more
core   +1 more source

Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study

Clinical Rheumatology, 2022
To evaluate retention, efficacy, and safety of subcutaneous (SC) abatacept over 2 years in patients with moderate-to-severe RA in the Abatacept SubCutaneOus in Routine clinical practicE (ASCORE) study.
R. Alten, X. Mariette, R. Flipo, R. Caporali, M. Buch, Y. Patel, S. Marsal, R. Sanmartí, M. Nurmohamed, H. Griffiths, P. Peichl, B. Bannert, M. Chartier, S. Connolly, K. Lozenski, C. Rauch   +15 more
semanticscholar   +1 more source

Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

RMD Open, 2022
Objective To investigate correlations between biomarkers of bone remodelling and extracellular matrix turnover with baseline disease activity and treatment response in patients with early rheumatoid arthritis (RA).Methods Assessing Very Early Rheumatoid ...
Roy Fleischmann, Yoshiya Tanaka, Paul Emery, Vivian P Bykerk, Sean E Connolly, Chun Wu, Robert Wong, Jinqi Liu, Peter Schafer, Yanhua Hu, Anne-Christine Bay-Jensen, Signe Holm Nielsen, Thomas WJ Huizinga   +12 more
doaj   +1 more source